UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

_____________________

FORM 8-K

_____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~March 263, 2026

_____________________

DELCATH SYSTEMS, INC.

(Exact Name of Registrant as Specified in its Charter)

_____________________

Delaware

001-16133

06-1245881

(State or other jurisdiction of

incorporation or organization)

(Commission

File Number)

(IRS Employer

Identification No.)

566 Queensbury Avenue

Queensbury, NY 12804

(Address of principal executive offices) (Zip Code)

(~~518~~212) ~~743~~489-~~8892~~2100

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of each exchangeon which registered

~~Trading~~

~~Name of each exchange~~

symbol(s)

on which registered

Common Stock, $.01 par value

DCTH

The Nasdaq Capital Market

Common Stock, $.01 par value

DCTH

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 28.02 01 Other Events.

~~Results~~CHOPIN ofStudy ~~Operations and Financial Condition.~~

On ~~February~~March 263, 2026, Delcath Systems, Inc. ~~(“Delcath”)~~ issued a press release announcing ~~financial~~publication ~~results~~of ~~and~~CHOPIN ~~business~~clinical ~~highlights~~trial ~~for~~results ~~the~~in ~~year and quarter ended December 31, 2025 (~~the ~~“Press~~Lancet ~~Release”)~~Oncology. A copy of the press release is furnished ~~pursuant to Item 2.02~~ as Exhibit 99.1 ~~hereto and is incorporated herein by reference~~.

~~The~~Item information contained in this Current Report on Form 8-K, including the Press Release, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended9.01 ~~The~~Financial ~~information~~Statements ~~contained herein~~ and ~~in the Press Release shall not be incorporated by reference into any filing with the U~~Exhibits.~~S. Securities and Exchange Commission by Delcath whether made before or after the date hereof, regardless of any general incorporation language in such filing.~~

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description	~~Description~~
99.1	Press Release (CHOPIN Clinical Trial Results in The Lancet Oncology), dated March 3, 2026.	~~Press Release, dated February 26, 2026~~
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).	~~Cover Page Interactive Data File (embedded within the Inline XBRL document)~~

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	~~DELCATH SYSTEMS, INC.~~	DELCATH SYSTEMS, INC.
Date: February 26, 2026	By:			/s/ Gerard Michel
Date: March 3, 2026		By:	/s/ Gerard Michel
				Name: Gerard Michel
		Name:	Gerard Michel
				Title: Chief Executive Officer
		Title:	Chief Executive Officer

Filing Compare · DELCATH SYSTEMS, INC.